Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080992857> ?p ?o ?g. }
- W2080992857 endingPage "5690" @default.
- W2080992857 startingPage "5675" @default.
- W2080992857 abstract "The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure–activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients." @default.
- W2080992857 created "2016-06-24" @default.
- W2080992857 creator A5001591869 @default.
- W2080992857 creator A5005363875 @default.
- W2080992857 creator A5010721455 @default.
- W2080992857 creator A5013542315 @default.
- W2080992857 creator A5015548248 @default.
- W2080992857 creator A5017136822 @default.
- W2080992857 creator A5017354438 @default.
- W2080992857 creator A5019103452 @default.
- W2080992857 creator A5020736516 @default.
- W2080992857 creator A5021004010 @default.
- W2080992857 creator A5022352605 @default.
- W2080992857 creator A5032103782 @default.
- W2080992857 creator A5032206966 @default.
- W2080992857 creator A5033182207 @default.
- W2080992857 creator A5035422570 @default.
- W2080992857 creator A5036730904 @default.
- W2080992857 creator A5039877495 @default.
- W2080992857 creator A5046911005 @default.
- W2080992857 creator A5051069913 @default.
- W2080992857 creator A5053061201 @default.
- W2080992857 creator A5056100384 @default.
- W2080992857 creator A5056407608 @default.
- W2080992857 creator A5062697954 @default.
- W2080992857 creator A5063656029 @default.
- W2080992857 creator A5063702945 @default.
- W2080992857 creator A5065664689 @default.
- W2080992857 creator A5067726260 @default.
- W2080992857 creator A5068252474 @default.
- W2080992857 creator A5071010224 @default.
- W2080992857 creator A5075700399 @default.
- W2080992857 creator A5075828178 @default.
- W2080992857 creator A5077715966 @default.
- W2080992857 creator A5078854539 @default.
- W2080992857 creator A5082415242 @default.
- W2080992857 creator A5084059598 @default.
- W2080992857 creator A5084858800 @default.
- W2080992857 creator A5086429917 @default.
- W2080992857 creator A5090325950 @default.
- W2080992857 creator A5090556428 @default.
- W2080992857 creator A5090815103 @default.
- W2080992857 date "2013-06-26" @default.
- W2080992857 modified "2023-10-14" @default.
- W2080992857 title "Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials" @default.
- W2080992857 cites W1976851503 @default.
- W2080992857 cites W1982077858 @default.
- W2080992857 cites W1987144475 @default.
- W2080992857 cites W1988726224 @default.
- W2080992857 cites W1988851207 @default.
- W2080992857 cites W1994438989 @default.
- W2080992857 cites W1998371249 @default.
- W2080992857 cites W2002378649 @default.
- W2080992857 cites W2009511212 @default.
- W2080992857 cites W2010978319 @default.
- W2080992857 cites W2014639631 @default.
- W2080992857 cites W2016692297 @default.
- W2080992857 cites W2020666187 @default.
- W2080992857 cites W2022714032 @default.
- W2080992857 cites W2026002143 @default.
- W2080992857 cites W2027861101 @default.
- W2080992857 cites W2031196045 @default.
- W2080992857 cites W2032740657 @default.
- W2080992857 cites W2037930459 @default.
- W2080992857 cites W2038586807 @default.
- W2080992857 cites W2042028319 @default.
- W2080992857 cites W2049643200 @default.
- W2080992857 cites W2052647859 @default.
- W2080992857 cites W2055402151 @default.
- W2080992857 cites W2056454032 @default.
- W2080992857 cites W2061278019 @default.
- W2080992857 cites W2066417528 @default.
- W2080992857 cites W2076011370 @default.
- W2080992857 cites W2097757428 @default.
- W2080992857 cites W2104830962 @default.
- W2080992857 cites W2111254482 @default.
- W2080992857 cites W2122800348 @default.
- W2080992857 cites W2124478432 @default.
- W2080992857 cites W2124903560 @default.
- W2080992857 cites W2132529559 @default.
- W2080992857 cites W2145934373 @default.
- W2080992857 cites W2150424194 @default.
- W2080992857 cites W2157704311 @default.
- W2080992857 cites W2158345238 @default.
- W2080992857 cites W2160234571 @default.
- W2080992857 cites W2170144893 @default.
- W2080992857 cites W2320144693 @default.
- W2080992857 cites W2321522369 @default.
- W2080992857 cites W2999957796 @default.
- W2080992857 doi "https://doi.org/10.1021/jm400402q" @default.
- W2080992857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23742252" @default.
- W2080992857 hasPublicationYear "2013" @default.
- W2080992857 type Work @default.
- W2080992857 sameAs 2080992857 @default.
- W2080992857 citedByCount "349" @default.
- W2080992857 countsByYear W20809928572013 @default.
- W2080992857 countsByYear W20809928572014 @default.
- W2080992857 countsByYear W20809928572015 @default.